Niacin (vitamin B3)

Mechanism of action

After absorption, nicotinic acid and nicotinamide are converted into NAD/NADP through salvage pathways and de novo synthesis (from tryptophan). NAD acts as a redox coenzyme (NAD+/NADH) and as a substrate for NAD-consuming enzymes (e.g. sirtuins, PARP, CD38), involved in DNA repair, epigenetic regulation, and calcium signaling. Nicotinic acid, at pharmacological doses, also activates the GPR109A (HCAR2) receptor on immune cells and adipocytes, contributing to effects on lipolysis and inflammatory mediators; activation of GPR109A is associated with “flushing” via prostaglandins. Nicotinamide does not significantly activate GPR109A and generally does not cause flushing, but at high doses it can still produce adverse effects (e.g. gastrointestinal, hepatic in some contexts).

Supported benefits

• Correction/prevention of vitamin B3 deficiency and pellagra (in contexts of insufficient intake or malabsorption) (strong)
• Support for energy metabolism through increased availability of NAD/NADP (basic biology is well established; translation into improved cognitive performance in healthy individuals has not been robustly demonstrated) (moderate)
• Effects on lipid profile with nicotinic acid at pharmacological doses (reduction in triglycerides and LDL, increase in HDL), but with clinical limitations and tolerability issues; this is not a nootropic benefit (strong)
• Possible reduction in certain dermatological outcomes (e.g. prevention of some non-melanoma skin cancers with nicotinamide in high-risk populations), not directly related to the focus (moderate)
• Improvement in attention/memory in healthy individuals or as a nootropic: direct evidence is limited; any benefits are more plausible in cases of deficiency or increased requirement (limited)

Safety & side effects

• Flushing (redness, warmth, itching), more common with immediate-release nicotinic acid; mediated by prostaglandins
• Gastrointestinal disturbances (nausea, dyspepsia, diarrhea)
• Headache, dizziness
• Increased liver enzymes and hepatotoxicity (greater risk with high doses and some extended-release formulations)
• Worsening of glycemic control/insulin resistance in some individuals at high doses
• Hyperuricemia and possible worsening of gout at high doses
• Rare: myopathy, especially in combination with other lipid-lowering drugs

FAQ

Are niacin and niacinamide the same thing?

They are different forms of vitamin B3. Both contribute to the synthesis of NAD/NADP, but nicotinic acid (niacin) activates GPR109A and is more associated with flushing and pharmacological effects on lipids; nicotinamide (niacinamide) generally does not cause flushing and has a different action profile.

Does niacin really improve focus and memory?

The biological foundations (the role of NAD in neuronal metabolism) are solid, but evidence of measurable improvement in focus/memory in healthy people with adequate vitamin B3 intake is limited. Benefits are more plausible in cases of deficiency or increased requirement.

What is the “niacin flush” and why does it happen?

It is a vasodilation reaction with redness and a sensation of warmth/itching, typical of nicotinic acid. It is mediated in part by the release of prostaglandins following activation of receptors such as GPR109A.

Are extended-release forms safer?

Not necessarily. They may reduce flushing, but some extended-release formulations have been associated with a higher risk of liver abnormalities compared with immediate-release forms, especially at high doses.

What are the signs of possible intolerance or risk?

Severe flushing, persistent nausea, abdominal pain, dark urine, jaundice, marked fatigue, or generalized itching may be signs of problems (particularly liver-related) and require clinical evaluation.